Covid-19. To manufacture and evaluate the safety, efficacy and tolerability of galidesivir a broad spectrum, antiviral therapeutic.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00055
- Awardee
-
Biocryst Pharmaceuticals Inc. UEI MGXADJ6SCLJ5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,614,652
Award facts
- Opportunity
-
- 2020 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · HHSNIHNIAIDBAA20201 · Posted Dec 11, 2019
- COVID-19: HHS-NIH-NIAID-BAA2020-1: Research Area 004, Development of Therapeutics Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases Award Notice · Posted Aug 31, 2020
- 2020 NIAID Omnibus Broad Agency Announcement Solicitation · Posted Jan 3, 2020
- Contract value 7% obligated
-
- $2,614,651.55 Current, with exercised options
- $40,195,774.55 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ12 General Science And Technology R&D Services; General Science And Technology; Applied Research
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 23 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Durham, NC 27703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$3,711,828 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $6,326,480 |
About this award
This is a $40,195,774.55 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to BioCryst Pharmaceuticals Inc. to manufacture and evaluate the safety, efficacy, and tolerability of the antiviral therapeutic galidesivir as a potential COVID-19 treatment. The contract has a period of performance through September 30, 2022 and does not carry a set-aside designation.
BioCryst Pharmaceuticals is a biotechnology company that specializes in developing small molecule drugs, primarily for rare diseases. The company has an active Federal Supply Schedule contract with the Department of Veterans Affairs for its pharmaceutical products, including ORLADEYO for hereditary angioedema and RAPIVAB for influenza treatment. This award supplements BioCryst's existing federal contracting work to support the development of a COVID-19 therapeutic.
Quick answers
Who was awarded contract 75N93020C00055?
75N93020C00055 was awarded to Biocryst Pharmaceuticals Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2020.
How much is contract 75N93020C00055 worth?
The government has obligated $2,614,652 on 75N93020C00055. Its potential value, with all options, is $40,195,775.
Was contract 75N93020C00055 competed?
The extent of competition for 75N93020C00055 was full and open competition. The government received 23 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award